Skip to main content

Bullous Pemphigoid News

Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

TARRYTOWN, N.Y. and PARIS, June 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dup...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

prednisone, doxycycline, methotrexate, Dupixent, erythromycin, prednisolone, etanercept, rituximab, tetracycline, dupilumab